Trials that use: Multiple imputation / missing data
New to this method? Read the tutorial →
7,624 results
- A Study of Paliperidone Palmitate 6-Month Formulation: Complete Statistical AnalysisIndependent statistical analysis of A Study of Paliperidone Palmitate 6-Month Formulation: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03345342).
- A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low Emetogenic Chemotherapy (LEC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Participants Who Have Experienced CINV(Chemotherapy-Induced Nausea and Vomiting) During the Previous Cycle of Low…
- A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin’s Lymphoma Grades 1, 2 or 3a: Complete Statistical AnalysisIndependent statistical analysis of A Study of Participant Preference With Subcutaneous Versus Intravenous MabThera/Rituxan in Participants With CD20+ Diffuse Large B-Cell Lymphoma or CD20+ Follicular Non-Hodgkin's Lymphoma Grades 1, 2 or 3a:…
- A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: Complete Statistical AnalysisIndependent statistical analysis of A Study of Patients Who Received Inotuzumab Ozogamicin for B-cell ALL (Acute Lymphoblastic Leukemia) That Occurred Again After the Last Treatment: primary endpoint results, effect estimate with confidence…
- A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).: Complete Statistical AnalysisIndependent statistical analysis of A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) in Patients With Hepatitis Be Antigen (HBeAg) Positive Chronic Hepatitis B (CHB).: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) – Positive Chronic Hepatitis B: Complete Statistical AnalysisIndependent statistical analysis of A Study of Peginterferon Alfa-2a (40KD) (PEGASYS®) in Participants With Hepatitis B Envelope Antigen (HBeAg) - Positive Chronic Hepatitis B: primary endpoint results, effect estimate with confidence interval,…
- A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD): Complete Statistical AnalysisIndependent statistical analysis of A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin’s Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed or Refractory Primary Mediastinal Large B-cell Lymphoma (rrPMBCL) (MK-3475-B68): primary endpoint results, effect…
- A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab (MK-3475) Versus Paclitaxel, Docetaxel, or Vinflunine for Participants With Advanced Urothelial Cancer (MK-3475-045/KEYNOTE-045): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pembrolizumab Plus Epacadostat With Platinum-based Chemotherapy Versus Pembrolizumab Plus Platinum-based Chemotherapy Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-715-06/ECHO-306-06): primary endpoint results, effect estimate…
- A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC): primary…
- A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed and Cyclophosphamide Given Every 21 Days in Advanced Breast Cancer Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pemetrexed in Recurrent Cervical Adenocarcinomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02868892).
- A Study of Pertuzumab in Participants With Metastatic Breast Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab in Participants With Metastatic Breast Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02491892).
- A Study of Pertuzumab in Participants With Prostate Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab in Participants With Prostate Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02480010).
- A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): Complete Statistical AnalysisIndependent statistical analysis of A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pevonedistat in People With Blood Cancers or Solid Tumors With Kidney or Liver Problems: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer’s Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-04447943 Compared To Placebo In Subjects With Mild To Moderate Alzheimer's Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-04449913 In Japanese Patients With Select Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study Of PF-04449913 In Select Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-04449913 In Select Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00953758).
- A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study Of PF-06664178 In Patients With Advanced Solid Tumors: Complete Statistical AnalysisIndependent statistical analysis of A Study Of PF-06664178 In Patients With Advanced Solid Tumors: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02122146).
- A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation: Complete Statistical AnalysisIndependent statistical analysis of A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection…
- A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed Non-Hodgkin’s Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of A Study Of Pharmacokinetics, Whole Body And Organ Dosimetry, And Biodistribution Of Fission-Derived Iodine I 131 Tositumomab (BEXXAR®) For Patients With Previously Untreated Or Relapsed Follicular Or Transformed…
- A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Radiation Therapy and Paclitaxel and Carboplatin in Patients With Uterine Papillary Serous Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ramucirumab in Participants With Metastatic Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02): Complete Statistical AnalysisIndependent statistical analysis of A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: Complete Statistical AnalysisIndependent statistical analysis of A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD): Complete Statistical AnalysisIndependent statistical analysis of A Study of Recombinant Von Willebrand Factor (rVWF) in Pediatric and Adult Participants With Severe Von Willebrand Disease (VWD): primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer: Complete Statistical AnalysisIndependent statistical analysis of A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis: Complete Statistical AnalysisIndependent statistical analysis of A Study of Rizatriptan for the Treatment of Acute Migraine in Patients on Topiramate for Migraine Prophylaxis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.: Complete Statistical AnalysisIndependent statistical analysis of A Study of RO4607381 in Patients With Coronary Heart Disease (CHD) or a CHD Risk Equivalent.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF: Complete Statistical AnalysisIndependent statistical analysis of A Study of RoActemra/Actemra (Tocilizumab) in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to DMARDs or Anti-TNF: primary endpoint results, effect estimate with confidence interval, sample-size…
- A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis: Complete Statistical AnalysisIndependent statistical analysis of A Study of RoActemra/Actemra (Tocilizumab) Versus Placebo in Patients With Systemic Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty: Complete Statistical AnalysisIndependent statistical analysis of A Study of Ropivacaine Complex Methylene Blue Fascia Iliaca Compartment Block on Analgesia in Patients Undergoing Hip Arthroplasty: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease: Complete Statistical AnalysisIndependent statistical analysis of A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies: Complete Statistical AnalysisIndependent statistical analysis of A Study of Sacituzumab With Chemoimmunotherapy to Treat Advanced Triple-Negative Breast Cancer After Prior Therapies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients: Complete Statistical AnalysisIndependent statistical analysis of A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016): Complete Statistical AnalysisIndependent statistical analysis of A Study of Safety and Efficacy of Vaniprevir Administered With Pegylated-Interferon and Ribavirin in Japanese Participants With Chronic Hepatitis C Infection (7009-016): primary endpoint results, effect estimate with…
- A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201): Complete Statistical AnalysisIndependent statistical analysis of A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201): primary endpoint results, effect estimate with confidence interval,…
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204): Complete Statistical AnalysisIndependent statistical analysis of A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204): primary endpoint results, effect estimate…
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202): Complete Statistical AnalysisIndependent statistical analysis of A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202): primary endpoint results, effect estimate with…
- A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia: Complete Statistical AnalysisIndependent statistical analysis of A Study of Sativex® for Pain Relief of Peripheral Neuropathic Pain, Associated With Allodynia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.: Complete Statistical AnalysisIndependent statistical analysis of A Study of Sativex® for Relief of Peripheral Neuropathic Pain Associated With Allodynia.: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas: Complete Statistical AnalysisIndependent statistical analysis of A Study of Saxagliptin in Subjects With Type 2 Diabetes Who Have Inadequate Blood Sugar Control With Sulfonylureas: primary endpoint results, effect estimate with confidence interval, sample-size planning…